The present invention relates to an optimized fermentation process of coenzyme Q10, particularly to a fermentation process of coenzyme Q10 via flow feeding based on cooperative control of changes of online oxygen consumption rate and conductivity. During the fermentation process of coenzyme Q10 production strains, the oxygen consumption rate is controlled between 30-150 mmol/L.Math.h and the conductivity is maintained between 3.0-30.0 ms/cm via flow feeding, so as to facilitate strain growth and the start of coenzyme Q10 synthesis and accumulation. The present invention can substantially increase output of coenzyme Q10 and greatly reduce the production cost with simple process control and strong operability, thus being applicable to large-scale industrial production.

The present invention describes a reduction type coenzyme Q10 powder, a composition thereof, and a preparation method thereof. The reduction type coenzyme Q10 powder is obtained by reacting an oxidation type coenzyme Q10 with the presence of a reducing agent, removing an organic solvent and other purities from a reaction solution after the reaction is finished to obtain an oil-soluble reduction type coenzyme Q10 liquid, and then directly performing prill formation with cold wind on an obtained reduction type coenzyme Q10 greasy substance. The obtained reduction type coenzyme Q10 powder has a lower crystallinity, and in a Cu-K[alpha] X-ray diffraction spectrum, has a strong peak at a diffraction angle 2[theta] being 18.9 DEG, and has a very strong absorption peak at a diffraction angle 2[theta] being 22.8 DEG. The reduction type coenzyme Q10 powder obtained in the present invention is in an incompletely crystallized state, has desirable stability and desirable oral bioavailability, and is suitable for use in applications such as dietary supplements, cosmetics or pharmaceuticals.

The present invention describes a reduction type coenzyme Q10 powder, a composition thereof, and a preparation method thereof. The reduction type coenzyme Q10 powder is obtained by reacting an oxidation type coenzyme Q10 with the presence of a reducing agent, removing an organic solvent and other purities from a reaction solution after the reaction is finished to obtain an oil-soluble reduction type coenzyme Q10 liquid, and then directly performing prill formation with cold wind on an obtained reduction type coenzyme Q10 greasy substance. The obtained reduction type coenzyme Q10 powder has a lower crystallinity, and in a Cu-K[alpha] X-ray diffraction spectrum, has a strong peak at a diffraction angle 2[theta] being 18.9 DEG, and has a very strong absorption peak at a diffraction angle 2[theta] being 22.8 DEG. The reduction type coenzyme Q10 powder obtained in the present invention is in an incompletely crystallized state, has desirable stability and desirable oral bioavailability, and is suitable for use in applications such as dietary supplements, cosmetics or pharmaceuticals.

The present invention relates to isolated polypeptides having peroxygenase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

The present invention relates to isolated polypeptides having peroxygenase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

A process for producing reduced coenzyme Q.sub.10 includes removing moisture from an aqueous suspension including a reduced coenzyme Q.sub.10-containing microbial cell or a disrupted cell thereof such that a de-moisturized substance is obtained and in contact with an oxidizing atmosphere, and that an oxidized coenzyme Q.sub.10 is produced in an amount of 50 mass % or more relative to a total amount of the oxidized and reduced coenzymes Q.sub.10, and reducing the oxidized coenzyme Q.sub.10 outside a microbial cell such that a reduced coenzyme Q.sub.10 is recovered.

A process for producing on an industrial scale the oxidized coenzyme Q.sub.10, includes culturing a reduced coenzyme Q.sub.10-producing microorganism selected from the group consisting of the genus Rhodobacter, the genus Saitoella, the genus Schizosaccharomyces and the genus Trichosporon, to obtain microbial cells containing reduced coenzyme Q.sub.10 at a ratio of not less than 70 mole % among the entire coenzymes Q.sub.10; and one of: (a) oxidizing thus-obtained reduced coenzyme Q.sub.10 to oxidized coenzyme Q.sub.10 and then extracting the oxidized coenzyme Q.sub.10 by an organic solvent; or (b) extracting reduced coenzyme Q.sub.10 by an organic solvent and oxidizing the extracted reduced coenzyme Q.sub.10 to oxidized coenzyme Q.sub.10.

A process for producing on an industrial scale the oxidized coenzyme Q.sub.10, includes culturing a reduced coenzyme Q.sub.10-producing microorganism selected from the group consisting of the genus Rhodobacter, the genus Saitoella, the genus Schizosaccharomyces and the genus Trichosporon, to obtain microbial cells containing reduced coenzyme Q.sub.10 at a ratio of not less than 70 mole % among the entire coenzymes Q.sub.10; and one of: (a) oxidizing thus-obtained reduced coenzyme Q.sub.10 to oxidized coenzyme Q.sub.10 and then extracting the oxidized coenzyme Q.sub.10 by an organic solvent; or (b) extracting reduced coenzyme Q.sub.10 by an organic solvent and oxidizing the extracted reduced coenzyme Q.sub.10 to oxidized coenzyme Q.sub.10.

Two novel cytochrome P450 genes are isolated from sorghum, each gene encoding a protein having pentadecatrienyl resorcinol hydroxylase activity. Expression vectors containing these sequences are made and used to elevate levels of pentadecatrienyl resorcinol hydroxylase in transgenic cells and organisms.

Two novel cytochrome P450 genes are isolated from sorghum, each gene encoding a protein having pentadecatrienyl resorcinol hydroxylase activity. Expression vectors containing these sequences are made and used to elevate levels of pentadecatrienyl resorcinol hydroxylase in transgenic cells and organisms.